Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningitis
Meningococcal Meningitis
Meningococcal Infections

Interventions

BIOLOGICAL: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate
BIOLOGICAL: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company